TRIAL: Treatment of Respiratory Infections with inhaled AntimicrobiaLs

试验：用吸入抗菌药物治疗呼吸道感染

• 批准号: EP/W016389/1
• 负责人: Raechelle D'Sa
• 金额: $ 84.6万
• 依托单位: University of Liverpool
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FW016389%2F1
• 关键词: TRIAL; Treatment; Respiratory; Infections; inhaled

The coronavirus disease (COVID-19) pandemic caused by the global spread of the severe acute respiratory syndrome-2 (SARS-CoV-2) virus has led to a staggering number of deaths worldwide and significantly increased burden on healthcare as nations have scrambled to find mitigation strategies. Viral infections such as SARS-CoV-2 can also predispose patients to bacterial co-infections. In fact, at least one in seven patients who have tested positive for COVID-19 have developed bacterial co-infections which have increased the severity and mortality of the disease. Since antiviral drugs have no effect on bacterial infections, these co-infections are treated with antibiotics. This surge in the use of antibiotic use during the COVID-19 pandemic has a detrimental effect in terms of driving the global growth of antibiotic resistance. The goal of TRIAL is to design and test drug delivery vehicles tethered with antimicrobials to deliver the requisite therapeutic dose to tackle viral and bacterial infections in a controlled manner. The antimicrobials that are being developed in our laboratory have shown to have an effect on a wide range of respiratory viruses and bacterial pathogens. As we are using broad spectrum antimicrobials that are not antibiotics and we are therefore lowering the risk of developing antimicrobial resistance. The technology being developed here is highly novel and will be revolutionary in the treatment of respiratory infections including that of COVID-19. We have brought together a group of world-class scientists, a clinician and an industrial partner with over 20 years' experience in their respective fields who will work to achieve the ambitious goals of the proposed work. The long term goal is the acceleration of bench to clinic impact followed by the commercialisation of the technology.

由严重急性呼吸系统综合征-2（SARS-CoV-2）病毒全球传播引起的冠状病毒病（COVID-19）大流行导致全球死亡人数惊人，并显著增加了医疗保健的负担，因为各国都在争先恐后地寻找缓解策略。病毒感染，如SARS-CoV-2也可能使患者易患细菌合并感染。事实上，在COVID-19检测呈阳性的患者中，至少有七分之一出现了细菌合并感染，这增加了疾病的严重程度和死亡率。由于抗病毒药物对细菌感染没有效果，这些合并感染用抗生素治疗。COVID-19大流行期间抗生素使用的激增在推动全球抗生素耐药性增长方面产生了不利影响。TRIAL的目标是设计和测试与抗菌剂相连的药物递送载体，以提供必要的治疗剂量，以受控的方式应对病毒和细菌感染。我们实验室正在开发的抗菌剂已显示对广泛的呼吸道病毒和细菌病原体有影响。由于我们使用的是广谱抗菌剂，而不是抗生素，因此我们降低了产生抗菌素耐药性的风险。这里正在开发的技术非常新颖，将在包括COVID-19在内的呼吸道感染的治疗中具有革命性意义。我们汇集了一批世界一流的科学家、一名临床医生和一名在各自领域拥有20多年经验的工业合作伙伴，他们将努力实现拟议工作的宏伟目标。长期目标是加速实验室对临床的影响，然后将该技术商业化。